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Abstract Stop codon mutations in the gene encoding the
prion protein (PRNP) are very rare and have thus far only
been described in two patients with prion protein cerebral
amyloid angiopathy (PrP-CAA). In this report, we describe
the clinical, histopathological and pathological prion pro-
tein (PrPSc) characteristics of two Dutch patients carrying
novel adjacent stop codon mutations in the C-terminal part
of PRNP, resulting in either case in hereditary prion protein
amyloidoses, but with strikingly different clinicopatho-
logical phenotypes. The patient with the shortest disease
duration (27 months) carried a Y226X mutation and
showed PrP-CAA without any neurofibrillary lesions,
whereas the patient with the longest disease duration
(72 months) had a Q227X mutation and showed an unusual
Gerstmann-Stra¨ussler-Scheinker disease phenotype with
numerous cerebral multicentric amyloid plaques and severe
neurofibrillary lesions without PrP-CAA. Western blot
analysis in the patient with the Q227X mutation demon-
strated the presence of a 7 kDa unglycosylated PrPSc
fragment truncated at both the N- and C-terminal ends. Our
observations expand the spectrum of clinicopathological
phenotypes associated with PRNP mutations and show that
a single tyrosine residue difference in the PrP C-terminus
may significantly affect the site of amyloid deposition and
the overall phenotypic expression of the prion disease.
Furthermore, it confirms that the absence of the glycosyl-
phosphatidylinositol anchor in PrP predisposes to amyloid
plaque formation.
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Introduction
Transmissible spongiform encephalopathies, or prion dis-
eases, are fatal neurodegenerative disorders that can occur as
sporadic, inherited or acquired disorders. These diseases are
pathogenetically characterized by the accumulation of pro-
tease-resistant PrPSc, an abnormal structural conformer of
the normal cellular prion protein, PrPC. In humans, prion
diseases are classified into three major groups, showing a
wide phenotypic heterogeneity: Creutzfeldt-Jakob disease
(CJD), Gerstmann-Stra¨ussler-Scheinker disease (GSS) and
fatal insomnia (FI). While in most cases of CJD and in FI
PrPSc accumulates in brain parenchyma without significant
amyloid deposition, PrP-amyloid constitutes the dominant
type of abnormal PrPSc accumulation in GSS. This striking
phenotypic difference has a significant correlate at the
molecular level. Indeed, while in CJD and FI abnormal prion
protein deposits include both full-length PrPSc and truncated
fragments in the 12–21 kDa range, in GSS the dominant
PrPSc forms comprise 7–10 kDa unglycosylated fragments,
truncated at both the C-terminal and N-terminal end, lacking
the glycosylphosphatidylinositol (GPI) anchor [11, 24, 28].
To date, GSS has only been described in association
with prion protein gene (PRNP) mutations and is inherited
in an autosomal dominant manner. In its classic form, GSS
is characterized by a progressive cerebellar syndrome
accompanied by extrapyramidal and pyramidal signs and
cognitive decline, which may evolve into severe dementia
[11]. There is considerable heterogeneity, however, in age
at onset, disease duration and clinical symptoms, both
within and between families with the same mutation. Thus,
in some individuals, marked extrapyramidal signs with
Parkinsonism may occur early in the course of the disease,
whereas in others pyramidal signs, pseudobulbar signs or
dementia predominate. Neuropathological features associ-
ated with GSS vary substantially, but always include
multicentric amyloid plaques, which can be either the only
significant lesion or be associated with neurofibrillary
tangles or spongiform changes [11]. About 10-point
mutations in PRNP affecting various codons are known to
be associated with GSS. In addition, a GSS-like phenotype
has been described in patients with octapeptide repeat
insertions of 8 or 9 additional 24 base pair repeats [7].
Pure prion protein cerebral amyloid angiopathy (PrP-
CAA) is another form of hereditary prion protein amyloi-
dosis, albeit with a disease phenotype different from GSS.
In this rare variant, which thus far has only been reported in
two patients with nonsense mutations at codon 145
(Y145X) or 163 (Y163X) of PRNP, PrPSc depositions are
found in blood vessels, without co-localization of Ab
[9, 27].
We describe here two cases of inherited prion disease
carrying two novel consecutive stop codon mutations in the
PRNP C-terminus, resulting in a PrP-CAA in one case, and
in an unusual GSS phenotype with many neurofibrillary
tangles and relative sparing of the cerebellum in the other.
Patients and methods
Patient consent
In the Netherlands, all CJD autopsies are performed after
informed consent, including explicit permission to use
tissues for research.
Patient 1
A 55-year-old woman was referred to the neurologist
because of increasing cognitive impairment, forgetfulness
and decreased concentration over the previous 12 months.
The last week before admission, the patient had been
markedly affected by headaches and both acoustic and
visual hallucinations. On admission, she presented with
aphasia, in particular with difficulty in finding words. She
was disoriented and showed impaired memory and visuo-
spatial functioning. There were no pyramidal or
extrapyramidal signs, myoclonic jerks or cerebellar
symptoms. Brain magnetic resonance imaging showed
hyperintensity of the white matter, but no atrophy or
abnormalities in the basal ganglia. The 14-3-3 test in
cerebrospinal fluid was positive. An electroencephalogram
(EEG) showed generalized slowing with a typical pattern
of periodic synchronous wave complexes. During admis-
sion, she developed hyperactive tendon reflexes and
apraxia. After 2 months, she was transferred to a nursing
home, where she remained for 13 consecutive months.
During this period, she became increasingly agitated and
subsequently developed signs of Parkinsonism as a result
of neuroleptic treatment. She became akinetic and mute
with myoclonic jerks towards the end of the disease course.
Death occurred at the age of 57 years, 27 months after
onset of symptoms.
Of note was the patient’s mother had been diagnosed
with ‘‘probable CJD’’ on the basis of comparable symp-
toms and signs. Death occurred at the age of 75, 18 months
after onset of symptoms. Postmortem examination was not
performed.
Patient 2
A 42-year-old woman was referred to the neurologist for
the evaluation of a slowly progressive hypokinetic rigid
syndrome with cognitive decline. For the last two-and-a-
half years, she had experienced difficulties with finding
words and memory disturbance, and others had also
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noticed personality changes. Her medical history was
otherwise unremarkable. She suffered from a cramping,
stiff feeling in her legs and arms, right more than left. On
neurological examination, there was a masked face, a clear
dysarthria and variably raised muscle tone in arms and legs
with slight cogwheeling. All reflexes were normal and eye
movements were intact. There were neither hallucinations,
nor pyramidal or cerebellar signs. A CT scan of the brain
showed moderate atrophy of the left frontal lobe and less
severe atrophy of the left temporal lobe. EEG and 14-3-3
test were not performed. SPECT scan of the brain showed
hypoperfusion in the left frontal and temporal cortex
extending into the parietal cortex. She was clinically
diagnosed with frontotemporal dementia. Over the fol-
lowing 3 years her condition gradually deteriorated. She
suffered from a tremor in both her right hand and right foot,
developed epileptic seizures and became completely
dependent on care. During the last 2 months before death,
she became mute and the frequency of epileptic seizures
and spasms increased. She died at the age of 45 years,
72 months after clinical onset. In her family, one of her
father’s sisters had died at the age of 42 years with com-
parable symptoms.
Neuropathology
The brains from both patients were removed 24 h after
death. Samples of tissue from several brain regions of
patient 2 were frozen at -80C, whereas the whole brain
from patient 1 was fixed in formalin. A complete neuro-
pathological examination was performed, including gross
brain examination and microscopic examination of paraf-
fin-embedded sections from the grey and white matter of
all lobes of the brain, central nuclei (caudate, putamen,
pallidum and thalamus), cerebellum and brainstem. For
histological examination, formalin-fixed sections were
decontaminated for 1 h in 98% formic acid and embedded
in paraffin. Paraffin-embedded sections were cut at 5 lm
and stained routinely with haematoxylin–eosin and com-
bined Luxol-periodic acid-Schiff (PAS) stains. In addition,
sections were stained with methenamine silver for the
presence of senile plaques. The monoclonal antibody 3F4
(1:400, overnight at 4C, Signet Laboratories, Dedham,
MA, USA) was used for PrP immunohistochemistry. Pre-
treatment protocols for PrP staining involved antigen
retrieval by autoclaving in citric acid buffer pH 6.0 at
121C for 10 min followed by incubation with Proteinase
K (10 lg/mL, for 5 min at room temperature). Immu-
nolabelling was visualized using PowerVision labelled
with horseradish peroxidase (Immunologic, Duiven, The
Netherlands) and diaminobenzidine as chromogen (DAB,
Dako, Carpentaria, CA, USA). Other immunohistochemi-
cal stains included antibodies against Ab (Ab1–17, 1:400,
Dako, Glostrup, Denmark and Ab17–24 4G8, 1:5,000,
Senetek, Napa, CA, USA), phosphorylated tau (AT8 1:250,
Innogenetics, Gent, Belgium), 3R tau (RD3, 1:6,400,
Upstate, Temecula, CA, USA) and 4R tau (RD4, 1:200,
Upstate, Temecula, CA, USA).
Genetic analysis
Genomic DNA was extracted from peripheral blood (patient
1) or from frozen brain tissue (patient 2). Full sequence
analysis of the open reading frame (ORF) of PRNP was
carried out. The PRNP ORF was initially amplified as pre-
viously described [4]. The codon 129 genotype was then
examined by digestion with the restriction endonuclease Xce
I (Fermentas). Finally, the fragment encoding the PRNP
ORF was purified by denaturing high pressure liquid chro-
matography peak captured and run on a ABI 310 Sequencer
as previously described [3].
Biochemical studies
PrPSc was extracted from the temporal, occipital and cer-
ebellar cortices of patient 2 and characterized as previously
described [24, 25]. In particular, PrPSc typing was per-
formed both on crude homogenates [25], and after
purification of the protein in sarkosyl [24]. The following
mouse monoclonal antibodies recognizing different human
PrP epitopes were used as described [22]: 3F4 (residues
108–111), 12B2 (residues 89–93), Sha31 (residues 145–
152), and SAF60 (residues 157–161). For PrP deglycosy-
lation, denatured proteins were incubated with peptide N-
glycosidase F (PNGase F) following the instruction from
the manufacturer (New England Biolabs Inc., Beverly,
MA, USA).
Results
Genetic analysis
DNA analysis (Fig. 1) revealed two novel mutations (678
C[A in patient 1 and 679 C[T in patient 2), resulting in
premature stop codons (Y226X and Q227X). Both
patients were heterozygous for methionine and valine
at codon 129 and carried the mutation on the valine
allele.
Neuropathology
Patient 1 (Y226X mutation)
Gross examination of the brain (weight 1,300 g) was
unremarkable. The results of microscopic examination are
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summarized in Table 1. The main finding was a diffuse and
severe amyloid angiopathy involving small to medium-
sized arteries and arterioles of the cerebral and cerebellar
cortex and leptomeninges (Fig. 2a, c). Amyloid deposition
also involved the capillaries, as in CAA type 1 [30],
occasionally extending into the adjacent parenchyma,
corresponding to dyshoric angiopathy. Anti-PrP antibodies
intensely stained the CAA lesions (Fig. 2b, d, g). In addi-
tion, there was a faint, scattered, synaptic staining in the
grey matter of the cerebral cortex and parenchymal plaques
were observed in all brain regions examined. Immunohis-
tochemical stainings with both monoclonal anti-Ab
antibodies (Fig. 2h), Dako 1-17 and 4G8, were negative.
Focal, dot-like tau-accumulations were noted around blood
vessels with amyloid depositions throughout the cerebral
cortex (Fig. 2f) and the hippocampus. Neurofibrillary tan-
gles were absent.
Patient 2 (Q227X mutation)
Gross examination of the brain (weight 990 g) showed
atrophy of the frontal lobe and caudate nucleus, with
marked ventricular dilation. The substantia nigra was
slightly pale. Microscopic examination revealed scattered
status spongiosus in the second layer of the cerebral cortex.
Numerous multicentric and unicentric plaques were present
in all layers of the cerebral cortex, with frontotemporal
accentuation (Fig. 3a). Plaques were also present in the
subcortical nuclei, hippocampus, entorhinal cortex and
focally in the subcortical white matter (Table 1). The cer-
ebellum was relatively spared and only showed sparse
amyloid depositions (Fig. 3c). Several plaques were loca-
ted alongside capillaries, but no amyloid angiopathy was
seen. The substantia nigra showed marked loss of pig-
mented neurons. Immunohistochemical staining with anti-
tau, anti-RD3 and RD4 antibodies revealed numerous
tangles, neuropil threads and also dystrophic neuritis
around the plaques (Fig. 3e). The neurofibrillary tangles
and neuropil threads were seen throughout the cerebral
cortex (Fig. 3f), including the occipital lobe and striate
area, which in Alzheimer’s disease would correspond to
Braak stage VI [1]. The plaques themselves showed posi-
tive staining with mAbs against PrP (Fig. 3b, d), whereas
stainings with anti-Ab antibodies and methenamine silver
were negative (data not shown).
Biochemical studies
Western blot analysis of PK-treated brain homogenates
from patient 2 demonstrated the presence of a PrPSc frag-
ment with a molecular weight of approximately 7 kDa. The
analyses of partially purified (P3) PrP preparations in
sarkosyl showed that the fragment was already visible in
the PK-untreated preparations (Fig. 4). Furthermore, there
were neither PrPSc fragments in the 19–21 kDa range (i.e.
type 1 or type 2) nor protease-sensitive abnormally insol-
uble full-length PrPSc (i.e. full-length PrP, which remains
visible in the P3 fraction but disappears completely after
PK digestion), as previously described in GSS P102L [24]
(Fig. 4). The 7 kDa fragment was detected by all anti-
bodies directed to epitopes located between PrP residues 89
and 112, while weak staining was observed with the anti-
body Sha31 (residues 145–152) and absent with the
antibody SAF60 (residues 157 and 161) (data not shown).
Furthermore, the electrophoretic mobility of the fragment
did not change after N-linked deglycosylation (Fig. 4).
Thus, epitope mapping combined with relative molecular
mass analyses indicated that the fragment is unglycosylated
and truncated at both the N- and C-terminal ends (around
residues 145–150), just as the previously described frag-
ment characterized in GSS cases carrying different PRNP
mutations [26].
Discussion
We describe two female Dutch patients with novel and
almost identical stop codon mutations in the C-terminal
part of PRNP, resulting in either case in hereditary prion
protein amyloidoses, but with strikingly different clinico-
pathological phenotypes. The Y226X mutation was
associated with pure PrP-CAA, also involving small
Fig. 1 Sequence analysis of PRNP of patients 1 and 2. Short
segments of PRNP of patient 1 with the Y226X mutation (upper part
of figure) and of patient 2 with the Q227X mutation (lower part of
figure) are shown. The insertion of either adenine (Y226X) or
thymine (Q227X) causes a premature stop codon
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arterioles and capillaries, without any neurofibrillary tan-
gles, whereas the Q227X mutation resulted in a GSS
disease phenotype with numerous multicentric amyloid
plaques and neurofibrillary lesions in the cerebral grey
matter and, remarkably, absence of PrP-CAA. Of note, the
latter case showed relative sparing of the cerebellum, a
rather unique feature in GSS, which has been only
described before in patients carrying the A117V-129V
haplotype [19]. This feature correlated with an atypical
clinical phenotype for GSS characterized by progressive
dementia with aphasia and personality changes without any
evidence of ataxia or pyramidal signs. A clinical phenotype
resembling frontotemporal dementia has been only repor-
ted before in GSS patients carrying the Q217R-129V
genotype [33], and in familial CJD subjects carrying the
T183A-129M haplotype [21].
Neurofibrillary degeneration is not uncommon in GSS
with long disease duration, having been described in
patients harbouring the A117V-129V, F198S-129V,
D202N-129V, P105L-129V and Q217R-129V haplotypes
Fig. 2 Histopathologic features
of PRNP-Y226X. Sections are
stained with haematoxylin–
eosin (a, c), Luxol-periodic
acid-Schiff reaction (e), 3F4
anti-PrP antibody (b, d, g), anti-
phosphorylated tau (AT8) (f)
and anti-Ab (h). Original
magnification 9100 (d), 9200
(a, b, c, h) and 9400 (e, f, g).
Amyloid angiopathy involving
small to medium-sized arteries,
arterioles (arrow) and
capillaries of the cerebral
(a, b, g) and cerebellar cortex
and leptomeninges (c, d).
Spongiform changes in the
parietal cortex with amyloid
depositions surrounding blood
vessels (e). Focal tau
accumulations around blood
vessels with amyloid
depositions in the temporal
cortex (f). Absence of staining
with anti-Ab antibodies (h)
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[8, 10, 20, 26, 34]. Furthermore, it has been found in
association with the Y145X, Y163X and Q227X mutations
(Table 2), as well as in variant CJD, a bovine-derived
acquired form of prion disease also characterized by
extensive amyloid deposition [12, 17]. Interestingly, our
patient with the Y226X mutation only showed focal tau
accumulations in the absence of tangles, possibly because
of the relatively short disease duration in this case. The
mechanism of neurofibrillary degeneration in prion dis-
eases still remains a largely unexplained phenomenon,
Table 1 Regional distribution of spongiosis, neuronal loss/gliosis, PrP deposits and tau accumulation
FC PC TC OC Hipp STR Th BRST CE
Y226X Spongiosis - ?/- - - - - - - -
Gliosis/neuronal loss ? ? ? ? ? ? ? ? -
Prion protein deposits ?? ?? ??? ??? ??? ? ?? ? ???
Tau accumulation Focal tau accumulation around blood vessels with amyloid deposits
Q227X Spongiosis - - - - - - - - -
Gliosis/neuronal loss ?? ?? ?? ? ? ?? ? ? ?
Prion protein deposits ??? ??? ??? ? ??? ?? ?? ? ?
Tau accumulation ??? ??? ??? ? ??? ??? ??? ? -
Each lesion was scored as not detectable (-), mild (?), moderate (??) and severe (???). The number of PrP deposits were counted per HPF
and scored as not detectable (-), 1–10 deposits (?), 11–20 deposits (??) and [20 deposits (???)
FC frontal cortex, PC parietal cortex, TC temporal cortex, OC occipital cortex, Hipp hippocampal formation, STR striatum, Th thalamus, BRST
brainstem, CE cerebellum
Fig. 3 Histopathologic features
of PRNP-Q227X. Sections are
stained with haematoxylin–
eosin (a), Luxol-periodic acid-
Schiff reaction (c), 3F4 anti-PrP
antibody (b, d) and anti-tau
antibody RD4 (e, f). Original
magnification 9200 (a, b, c, d)
and 9400 (e, f). Presence of
numerous multicentric and
unicentric plaques in the frontal
cortex (arrows) (a, b). Relative
sparing of the cerebellum with
sparse amyloid depositions
(arrow) (c, d). Dystrophic
neurites surrounding PrPSc
plaques and neuropil threads (e)
and neurofibrillary tangles (f)
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although the pathological features in our patient with the
Q227X mutation support previous findings indicating that
tau accumulation and tangle formation almost invariably
develop in the presence of parenchymal PrP amyloid
formation, paralleling what occurs in Alzheimer’s disease
[15]. These findings suggest a relationship between amy-
loid fibrils and the formation of abnormal tau deposits,
irrespective of the chemical type of amyloid, possibly
contradicting the hypothesis that monomeric mole-
cules, such as Ab, are the direct cause of tau accumulations
[14].
The term CAA is used to describe the pathological
process during which an amyloid protein is progressively
deposited in blood vessel walls with subsequent degener-
ative vascular changes [31]. Deposition of Ab in blood
vessels, by far the most common cause of CAA in humans,
has been also documented in CJD and GSS [13, 16, 18, 29].
In contrast, vascular deposits of PrP-amyloid are very rare
and usually co-localize with Ab [23, 32]. PrP-CAA,
without co-localization of Ab, has thus far only been
described in a single Japanese patient carrying a Y145X
stop codon PRNP mutation [9] and more recently in a
patient carrying a Y163X mutation [27] (Table 2).
Although this observation strongly suggests a link between
the formation of truncated PrPSc on one hand and PrP-CAA
on the other, its interpretation is difficult being limited to
single cases only. A third patient with a similar stop-codon
(Q160X) also presented with early onset dementia but,
unfortunately, information on the pathological phenotype
in this case is still lacking [6].
The Y226X and Q227X mutations differ from the pre-
viously reported truncating mutations since they result in
two C-terminally truncated proteins lacking almost only
the GPI anchor. Strikingly, the two proteins only differ in a
single tyrosine residue at the C-terminus. Data obtained
from cell culture models indicate that glycosylated
anchorless full-length PrPC has a longer half-life than
normal PrPC, is predominantly secreted and does not
localize to the plasma membrane, although it may remain
associated to some intracellular membranes without a
transmembrane topology [2]. Chesebro and colleagues [5]
have recently generated transgenic mice expressing full-
length prion protein lacking the GPI anchor. Interestingly,
when infected with scrapie these mice show extensive
PrPSc depositions in the form of amyloid plaques, rather
than the usual non-amyloid form of PrPSc, but lack clinical
signs [5]. In contrast, scrapie-infected transgenic mice
Fig. 4 PrPSc typing and characterization of PRNP-Q227X. Immuno-
blot analysis of partially purified, detergent insoluble, abnormal PrP
obtained from the frontal cortex of a sCJDVV2 case (lanes 1 and 3)
and patient 2 (lanes 2, 4, 5). Samples are without (lanes 1, 2) or with a
Proteinase K (PK) digestion step (lanes 3–5). The sample run in lane
5 was also deglycosylated with PNGaseF. Immunoblot was probed
with 3F4. The smears in lanes 2, 4 and 5 likely represent incompletely
solubilized (i.e. not monomeric) PrP-amyloid. Approximate molec-
ular masses are in kilodaltons
Table 2 Clinical features and neuropathological characteristics of reported patients with nonsense mutations in PRNP
Age at
onset
(years)
Disease
duration
(months)
Mutation Clinical features Pathological features Reference
38 252 Y145X,
129M
Slowly progressive dementia PrP amyloid deposits, PrP-CAA,
neurofibrillary tangles, no spongiosis
[9]
32–48 [72 Q160X,
129M
Slowly progressive dementia No postmortem [6]
n.a. n.a. Y163X,
129 n.d
n.a. PrP amyloid deposits, PrP-CAA,
neurofibrillary tangles
[27]
55 27 Y226X,
129V
Dementia, visual and acoustic
hallucinations
PrP amyloid deposits, PrP-CAA, focal tau
accumulations, mild focal spongiosis
Present report
39 72 Q227X,
129V
Dementia, extrapyramidal signs PrP amyloid deposits, neurofibrillary tangles,
no spongiosis
Present report
n.a. not available, n.d. not determined
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heterozygous for both wild-type and anchorless PrP,
developed clinical signs and died faster than the wild-type
mice, reflecting a situation similar to that in our patients.
Our observations confirm that the absence of a GPI-
anchor in PrPC predisposes to amyloid plaque formation
also in humans and therefore validate this animal model.
Interestingly, the ‘‘GPI-anchorless’’ transgenic mice also
showed perivascular depositions of PrP, similar to the
Y145X, Y163X and Y226X mutations in familial prion
disease. Why, in contrast, the Q227X PrP does not result
in a prion CAA in the patient described here remains
obscure, although it could be hypothesized that the two
C-terminal tyrosines somehow prevent or influence the
passage of the protein through the vessel wall. Further
studies are required to elucidate these pathogenetic
mechanisms in patients with pure PrP-CAA and stop
codon mutations in PRNP.
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